Voyager Therapeutics Income Statement (2014-2026) | VYGR

Income Statement Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
1.36M1.48M28.07M0.66M0.71M41.09M-1.55M150.48M4.90M4.60M90.11M19.50M29.60M24.63M6.30M6.50M5.20M13.40M15.37M2.59M
Operating items
Research & Development (Quarter)
19.50M17.91M14.02M14.35M12.53M19.34M14.55M18.57M21.98M25.86M25.76M27.09M34.45M30.24M35.58M31.53M31.33M35.87M35.95M24.60M
Selling, General & Administrative (Quarter)
10.44M8.71M8.35M7.66M7.55M7.31M8.46M9.03M8.29M8.26M10.24M8.61M10.15M8.17M8.99M9.64M10.49M8.09M9.32M8.26M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
29.94M26.63M22.37M22.01M20.08M26.64M23.01M27.60M30.28M34.12M36.00M35.70M44.60M38.41M44.58M41.17M41.83M43.96M45.27M32.86M
Operating Income (Quarter)
-28.59M-25.15M5.70M-21.35M-19.37M14.44M-24.56M122.88M-25.43M-29.51M-39.87M-16.18M-15.03M-13.78M-38.30M-34.69M-36.62M-30.59M-29.93M-30.27M
EBIT (Quarter)
-28.59M-25.15M5.70M-21.35M-19.37M14.44M-24.56M122.88M-25.43M-29.51M-39.87M-16.18M-15.03M-13.78M-38.30M-34.69M-36.62M-30.59M-29.93M-30.27M
Non-operating items
Interest & Investment Income (Quarter)
0.05M0.12M-0.64M0.03M0.22M0.55M0.98M1.86M3.27M3.43M3.15M4.87M4.89M4.58M3.99M3.29M2.83M2.38M2.11M1.91M
Other Non Operating Income (Quarter)
-1.58M-0.11M0.65M0.06M2.64M-0.02M0.00M0.02M0.20M0.40M0.42M0.43M0.40M0.40M0.43M
Non Operating Income (Quarter)
-1.53M-0.11M0.26M0.03M0.06M2.64M1.77M1.86M3.28M3.43M11.72M4.87M4.91M0.20M-13.93M3.71M0.43M0.40M11.02M0.43M
Net income details
EBT (Quarter)
-28.54M-25.02M5.06M-21.32M-19.09M17.62M-23.61M124.75M-22.15M-26.08M57.22M-11.32M-10.12M-9.00M-33.90M-30.98M-33.37M-27.81M-27.42M-27.92M
Tax Provisions (Quarter)
0.70M0.06M-0.18M0.82M0.01M0.02M0.04M0.58M0.04M0.01M0.08M0.01M0.01M
Profit After Tax (Quarter)
-30.12M-25.14M5.71M-21.32M-19.09M17.62M-23.63M124.04M-22.21M-25.90M56.40M-11.33M-10.14M-9.04M-34.49M-31.02M-33.38M-27.89M-27.43M-27.94M
Income from Continuing Operations (Quarter)
-28.54M-25.02M5.06M-21.32M-19.09M17.62M-23.61M124.04M-22.21M-25.90M56.40M-11.33M-10.14M-9.04M-34.49M-31.02M-33.38M-27.89M-27.43M-27.94M
Consolidated Net Income (Quarter)
-28.54M-25.02M5.06M-21.32M-19.09M17.62M-23.61M124.04M-22.21M-25.90M56.40M-11.33M-10.14M-9.04M-34.49M-31.02M-33.38M-27.89M-27.43M-27.94M
Income towards Parent Company (Quarter)
-28.54M-25.02M5.06M-21.32M-19.09M17.62M-23.61M124.04M-22.21M-25.90M56.40M-11.33M-10.14M-9.04M-34.49M-31.02M-33.38M-27.89M-27.43M-27.94M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-28.54M-25.14M5.71M-21.32M-19.09M17.62M-23.63M124.04M-22.21M-25.90M56.40M-11.33M-10.14M-9.04M-34.49M-31.02M-33.38M-27.89M-27.43M-27.94M
Additional items
EPS (Basic) (Quarter)
-0.80-0.670.15-0.56-0.500.46-0.623.05-0.51-0.591.23-0.20-0.18-0.16-0.60-0.53-0.57-0.47-0.47-0.47
EPS (Weighted Average and Diluted) (Quarter)
-0.80-0.670.15-0.56-0.500.45-0.622.94-0.51-0.591.19-0.20-0.18-0.16-0.60-0.53-0.57-0.47-0.47-0.47
Shares Outstanding (Weighted Average) (Quarter)
37.58M37.78M37.67M38.05M38.30M38.29M38.36M40.63M42.10M40.96M43.02M57.12M57.72M57.85M57.67M58.35M58.67M58.61M58.69M59.50M
Shares Outstanding (Diluted Average) (Quarter)
37.54M38.05M38.30M57.12M57.42M57.85M58.35M58.51M58.80M59.50M
EBITDA (Quarter)
-30.12M-25.14M5.70M-21.40M-19.23M17.65M-23.51M124.13M-22.21M-26.02M56.59M-11.79M-10.16M-8.55M-34.86M-30.81M-33.40M-27.66M-27.40M-28.23M
Interest Expenses (Quarter)
Tax Rate (Quarter)
0.56%-0.27%0.68%1.44%-0.12%-0.24%-0.48%-1.72%-0.12%-0.04%-0.30%-0.03%-0.05%